• Citer

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: Pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab

par Loibl, Sibylle;Loi, Sherene ;Untch, Michael;Conte, PierFranco;Bernards, René;Piccart-Gebhart, Martine ;Von Minckwitz, Gunter;Baselga, José;Majewski, Ian IJ;Guarneri, Valentina;Nekljudova, Valentina;Holmes, Eileen;Bria, Emilio;Denkert, Carsten;Schem, Christian;Sotiriou, Christos
Référence Annals of oncology, 27, 8, page (1519-1525)
Publication Publié, 2016-08

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: Pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
Auteur:	Loibl, Sibylle; Loi, Sherene; Untch, Michael; Conte, PierFranco; Bernards, René; Piccart-Gebhart, Martine; Von Minckwitz, Gunter; Baselga, José; Majewski, Ian IJ; Guarneri, Valentina; Nekljudova, Valentina; Holmes, Eileen; Bria, Emilio; Denkert, Carsten; Schem, Christian; Sotiriou, Christos
Informations sur la publication:	Annals of oncology, 27, 8, page (1519-1525)
Statut de publication:	Publié, 2016-08
Sujet CREF:	Hématologie
	Cancérologie
Mots-clés:	Double anti-HER2 treatment
	HER2+ breast cancer
	Neoadjuvant
	Pathological complete response
	PIK3CA
	Survival
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdw197
	info:pii/mdw197
	info:scp/84985015825
	info:pmid/27177864